The platform highlights structured learning opportunities focused on building expertise in environmental risk assessment methodologies for pharmaceuticals. Through collaborative training and exchange, it contributes to competence development across regulatory, academic, and research communities.

Explore the 2025 SSbD Boot Camp for updates on Safe and Sustainable by Design. Sessions cover the SSbD revision, scoping, safety and sustainability assessments, and documentation, supporting alternatives to substances of concern.

Explore the 2025 SSbD Boot Camp for updates on Safe and Sustainable by Design. Sessions cover the SSbD revision, scoping, safety and sustainability assessments, and documentation, supporting alternatives to substances of concern.

Explore the 2025 SSbD Boot Camp for updates on Safe and Sustainable by Design. Sessions cover the SSbD revision, scoping, safety and sustainability assessments, and documentation, supporting alternatives to substances of concern.

Focuses on key ethical and legal considerations involved in the collection of health information. It provides an introduction to the regulatory frameworks that govern the use of health data, highlighting the importance of accountability and compliance in research.

Recording of the 3 July 2025 PARC workshop presenting the alpha release of the SSbD toolbox. Includes an overview of its new interface, core functionalities, and practical use to support implementation of the European Commission’s Safe and Sustainable by Design framework.

Recording from Venice School 2025 provides an introduction to Life Cycle Assessment, highlighting essential methodologies and practical insights for evaluating environmental impacts across a product's lifecycle.

Focuses on showcasing FAIR data collections through the use of dashboards, highlighting how persistent identifiers (PIDs), well-structured metadata, and institutional data presentation can enhance transparency, accessibility, and reuse.

Presents the use of salivary leukocytes as a non-invasive biomatrix for assessing DNA damage and repair in biomonitoring studies using the comet assay, including methodological optimization and validation of both fresh and cryopreserved samples.

An in-depth look at the development and validation of QSAR models for chemical risk assessment, covering molecular descriptors, statistical modeling techniques, applicability domains, and the principles guiding regulatory acceptance.

Introduces the principles and applications of Non-Targeted Screening (NTS) using LC-HRMS, with emphasis on broader chemical characterisation, harmonised workflows, and methodological developments in the field.

An overview of in silico approaches in PARC, highlighting VEGA software and integrated platforms for assessing chemical properties aligned with SSbD principles.

This video introduces the Safe-and-Sustainable-by-Design (SSbD) approach in developing nano- and micro-pellets or capsules for cosmetics. Focusing on improved efficacy, controlled release, and sustainable material design.

Covers SSbD policy context, scoping actions, and a case-based walkthrough of the PLANETS Workflow, with full supporting materials and worksheet.

This video introduces the SSbD framework for University students and researchers, detailing its role in guiding safe and sustainable research and innovation.

The Data Management Tool developed for the INTEGRANO project is presented, highlighting its capacity to manage experimental and logistical data, support FAIR principles, and facilitate collaboration among research partners.

In this video an introduction to the SSbD Framework is provided, highlighting strategies for integrating safety and sustainability into research and innovation.

Key features of SSbD in wastewater treatment are discussed, including material synthesis, process efficiency, adaptability, and collaboration among stakeholders.

This video introduces the Safe and Sustainable by Design (SSbD) framework for the European textile industry, highlighting strategies for sustainability, regulatory compliance, and innovation across the supply chain.

This video presents an overview of SSbD in the cosmetics sector, focusing on innovation, supply chain impacts, and risk assessment of ingredients and processes.

This presentation focuses on the basic principles of matrix and biomarker selection in human biomonitoring, guiding participants from the identification of exposure biomarkers to their application in population studies. 

This presentation focuses on the core objectives of the HBM4EU project, providing a comprehensive overview of how each objective aligns with the project's work package structure. It highlights the strategic organisation of HBM4EU's activities and illustrates how the objectives collectively support the development of a coherent and policy-relevant human biomonitoring framework across Europe.

This presentation focuses on the role of human biomonitoring (HBM) in enhancing chemical risk assessment and supporting evidence-based policymaking. It highlights the need for reliable data on human exposure to chemicals across the EU, including variations over time, geography, and population sub-groups. The presentation also explores how HBM can inform policy by providing tools to interpret exposure data, assess health impacts, and monitor patterns and trends in chemical exposure across Europe.

This presentation focuses on exhaled breath condensate (EBC) as a biological matrix for chromium biomonitoring, explaining its production, potential applications, and the procedures for sample collection. It outlines the method developed by the Health & Safety Laboratory in the UK for chromium speciation in EBC, supported by findings from a feasibility study. 

This presentation focuses on the molecular pathways involved in the development of asbestos-related diseases, emphasising the roles of oxidative stress, DNA repair, and xenobiotic metabolism. It explores how both germline mutations and single-nucleotide polymorphisms (SNPs) within these pathways influence individual susceptibility. By understanding these mechanisms, researchers can identify clinically relevant biomarkers that support early diagnosis and risk assessment.

This presentation focuses on the fundamental terminology and principles of sampling, providing a clear overview of key concepts essential for designing and conducting human biomonitoring studies. It includes a brief introduction to the sample selection strategy developed for HBM4EU alignment studies.

This presentation provides a brief overview of key human biomonitoring (HBM) initiatives worldwide, offering insight into their scope and objectives. It includes a short introduction to the HBM4EU project, highlighting its role in coordinating efforts across Europe to advance the use of HBM in environmental health research and policymaking.

This presentation focuses on the use of blood and urine as primary biological media in HBM, outlining key characteristics of selected biomarkers in each matrix. It provides practical guidance on sample collection methods, highlighting potential pitfalls and necessary contingencies. Strategies for aliquoting and storage are discussed in detail, emphasising the importance of maintaining homogeneity in urine samples and the role of fractionation in sample pretreatment. Considerations for storage conditions, including cooling, freezing, and the use of preservatives, are also addressed to ensure sample integrity.

This presentation focuses on the concept and principles of Human Biomonitoring, specifically the classification and application of biomarkers, distinguishing between those used for exposure assessment, susceptibility evaluation, and research purposes. Highlights how the selection of specific biomarkers can provide insights into bioavailability and bioactivation over time, making them valuable tools for assessing aggregate exposure in diverse populations.

Focuses on the health risks associated with asbestos exposure, emphasizing its link to a range of diseases including asbestosis, pleural conditions, and multiple forms of cancer. Highlights malignant mesothelioma as a particularly aggressive cancer of the pleura and peritoneum, primarily caused by asbestos exposure. Discusses current challenges in diagnosing mesothelioma and the ongoing investigation into potential serum biomarkers, such as Soluble Mesothelin Related Protein (SMRP), Fibulin-3, and Survivin, for improving early detection and monitoring treatment response.